Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1653 1671
This examiner grants 55% of resolved cases
Jeffrey Mark Sifford is an examiner in Tech Center 1600 and Art Unit 1648. With 89 resolved cases, the examiner has an allowance rate of 55.1 percent. This 55.1 percent rate reflects a balanced examination environment, with over half of the cases reaching allowance. The data from these 89 resolved cases provides a baseline for understanding the examiner's tendencies.
The interview lift is 32.8 percent. This 32.8 percent lift suggests that interviews are a very effective way to improve the chances of an allowance. Practitioners should prioritize direct communication given this 32.8 percent increase over the base allowance rate. The impact of interviews is a significant factor in the 89 cases resolved by this examiner in Tech Center 1600.
The median days to allowance is 1223. This 1223-day duration provides a benchmark for the length of the prosecution cycle in Art Unit 1648. Practitioners can use this 1223-day median to set expectations for the duration of the examination process. The combination of the 55.1 percent allowance rate and the 1223-day median offers a clear path for strategic planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18569776 | CORONAVIRUS GLYCOSYLATION VARIANT VACCINES | Non-Final OA | ModernaTX, Inc. |
| 17911367 | KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME | Final Rejection | Wisconsin Alumni Research Foundation |
| 18022056 | ADENO-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED EXPRESSION LEVELS | Non-Final OA | California Institute of Technology |
| 17296829 | T Cell-Directed Anti-Cancer Vaccines Against Commensal Viruses | Non-Final OA | The General Hospital Corporation |
| 17412900 | Stable Reporter Flavivirus | Non-Final OA | Board of Regents, the University of Texas System |
| 17772996 | ARENAVIRUSES AS VECTORS | Final Rejection | UNIVERSITÄT BASEL |
| 18684161 | METHOD OF PRODUCING A FOOT AND MOUTH DISEASE VIRUS VIRUS-LIKE PARTICLE | Non-Final OA | Intervet Inc. |
| 18570077 | A SYSTEM AND METHOD FOR MONITORING THE EFFECT OF A HERPESVIRUS-BASED VACCINE IN AN ANIMAL POPULATION | Non-Final OA | INTERVET INC. |
| 18252624 | RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF | Non-Final OA | Intervet Inc. |
| 17791981 | SYSTEM AND METHOD FOR PROCESSING VIRUS PREPARATIONS TO REDUCE HETEROGENEITY | Final Rejection | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18037128 | REAL TIME PCR METHOD TO DETECT BOVINE PARVOVIRUS 3 | Non-Final OA | AMGEN INC. |
| 17802443 | METHOD FOR REMOVING HOST CELL DNA FROM VIRUS PREPARATION | Non-Final OA | Takeda Vaccines, Inc. |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | Final Rejection | TAKEDA VACCINES, INC. |
| 18058403 | ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2 | Non-Final OA | ARABIAN GULF UNIVERSITY |
| 18000638 | CHIMERIC ADENOVIRAL VECTORS | Non-Final OA | Vaxart, Inc. |
| 18007823 | ENHANCED PURIFICATION OF ADENO-ASSOCIATED VIRUS TO MORE EFFECTIVELY REMOVE CONTAMINATING DNA | Non-Final OA | Sartorius BIA Separations d.o.o. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy